Sagimet Biosciences (SGMT) reported that data from a Phase 3 clinical trial for the treatment of moderate to severe acne vulgaris conducted by Sagimet’s license partner for China, Ascletis Bioscience, will be presented at the 2025 Fall Clinical Dermatology Conference taking place October 24-26, 2025, in Las Vegas, Nevada. Key Presentation Highlights: Once daily oral 50 mg denifanstat achieved highly statistically significant and clinically meaningful improvements across all primary and secondary efficacy endpoints when analyzed using an intent-to-treat analysis. At Week 12, treatment success rates with denifanstat were more than double those of placebo, with marked reductions in both inflammatory and non-inflammatory lesions. Denifanstat was generally well-tolerated.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SGMT:
- Sagimet Biosciences Highlights Drug Development Success
- Sagimet Biosciences initiated with a Buy at Clear Street
- Sagimet Biosciences to present Phase 2b FASCINATE-2 study results
- Buy Rating for Sagimet Biosciences: Promising Clinical Developments and Synergistic Therapy Potential
- Sagimet announces dosing in Phase 1 PK trial of denifanstat with resmetirom